Urologic Cancers News
Combination therapy superior with respect to progression-free, overall survival and overall response for first-line treatment of advanced RCC.
Investigators found that the odds of locoregional recurrence of muscle-invasive bladder cancer following radical cystectomy depend on disease risk category.
A new algorithm developed by Canadian investigators aims to address underuse of cisplatin-based chemotherapy for muscle-invasive bladder cancer.
Under the accelerated approval program, if a confirmatory trial does not show clinical benefit, the FDA can take steps to remove the drug or indication.
AstraZeneca has voluntarily withdrawn durvalumab’s (Imfinzi’s) indication for adults with locally advanced or metastatic bladder cancer.
New study data offer insight on the mechanisms of angiotensin converting enzyme 2 (ACE2) in clear cell renal cell carcinoma (ccRCC).
In an online survey, 17.2% of patients with genitourinary cancers reported they delayed or avoided seeking medical care because of the COVID-19 pandemic.
Vicineum has been awarded a priority review for patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
Researchers analyzed data from patients with metastatic urothelial cancer to determine whether tumor mutation burden was associated with immune-related AEs among patients treated with immune checkpoint inhibitors.
Researchers sought to identify social disparities in diagnosis and treatment among patients with bladder cancer.
Researchers sought to determine accessibility and use of palliative care among patients with advanced renal cell carcinoma.
Using porcine bladders, researchers investigated whether bladder pressure affects the extent to which gemcitabine penetrates the bladder wall with this treatment modality.
Todd Bauer, MD, presents updated data from a phase 1/2 study of the oral hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan.
Investigators studied whether sexual orientation affects screening for prevalent gender-specific cancers including prostate, breast, and cervical cancer.
Lythgoe et al studied patterns of race reporting in genitourinary (GU) cancer trials.
A retrospective analysis evaluated the incidence of ONJ in patients who received VEGF-TKIs or immune-oncology therapy for mRCC and bone-targeted therapies for bone metastases.
A retrospective analysis sought to determine the effect of hypertension on overall survival, response, and progression-free survival in patients with mRCC.
A rise in neutrophil-to-lymphocyte ratio of 3 or more after 2 months of therapy is associated with an increased risk for death in less than 1 year and treatment failure in less than 6 months, according to investigators.
Patients with metastatic urothelial carcinoma have significantly longer overall survival when treated with a combination of radiotherapy and chemotherapy compared with chemotherapy alone, a study found.
Study findings support surveillance for urethral recurrence after radical cystectomy.